Overview

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

Status:
Recruiting

Trial end date:
2023-02-16

Target enrollment:

Participant gender:

Summary

This is a placebo-controlled clinical trial to assess whether Guanfacine Extended Release (GXR) reduces aggression and self injurious behavior in individuals with Prader Willi Syndrome (PWS). In addition, the study will establish the safety of GXR with a specific focus on metabolic effects.

Phase:

Phase 4

Details

Lead Sponsor:

Maimonides Medical Center

Treatments:

Guanfacine